CJC-1295 with DAC is a long-acting growth hormone-releasing hormone analog, while ipamorelin is a growth hormone secretagogue that acts through ghrelin receptors. Human studies show each can affect growth hormone signaling, but direct human trials of the combined stack are limited, and neither peptide is FDA-approved for patient use.
Wondering if sermorelin is right for you? Take the 3-min clinical quiz.
See if you qualify →What are CJC-1295 with DAC and ipamorelin?
CJC-1295 with DAC and ipamorelin are research peptides discussed together because both interact with the growth hormone pathway, but they do so in different ways. CJC-1295 with DAC acts like a long-acting growth hormone-releasing hormone analog, while ipamorelin is a growth hormone releasing peptide and ghrelin receptor agonist studied in human volunteers 1 3.
CJC-1295 with DAC in plain English
CJC-1295 is a synthetic GHRH analog, meaning it is designed to mimic growth hormone-releasing hormone signals sent to the pituitary gland. The “DAC” part stands for Drug Affinity Complex, a chemical feature that helps the peptide bind to albumin in blood and remain active longer than shorter GHRH fragments 1.
Ipamorelin in plain English
Ipamorelin acetate, also known in research as NNC 26-0161, is a growth hormone secretagogue. It acts through the growth hormone secretagogue receptor, GHS-R1a, which is part of the ghrelin signaling system that can trigger growth hormone release 3.
Why people search for them together
People search for CJC-1295 with DAC and ipamorelin together because the pairing is often described as a “dual-signal” stack: one peptide supports a GHRH-like signal, and the other activates a ghrelin-like secretagogue signal. That theory is biologically plausible, but direct human trials of the exact combined stack are lacking, so synergy claims should be treated as unproven 5 6.
How does CJC-1295 with DAC differ from CJC-1295 without DAC?
CJC-1295 with DAC is longer acting because the Drug Affinity Complex helps it bind to albumin. CJC-1295 without DAC is often used online to mean Modified GRF 1-29, a shorter-acting GHRH analog, but names are not always used carefully on research-product websites.
What DAC means
DAC means Drug Affinity Complex. In the CJC-1295 human trial, the peptide was described as a long-acting analog of growth hormone-releasing hormone that prolonged growth hormone and insulin-like growth factor 1, or IGF-1, exposure after administration in healthy adults 1.
Why CJC-1295 with DAC lasts longer
The DAC feature is meant to slow clearance from the body. That matters because longer exposure may produce a different growth hormone and IGF-1 pattern than a short pulse, which is one reason safety and lab monitoring questions are different from shorter-acting peptides 1 4.
Why CJC-1295 no DAC often means Modified GRF 1-29
Many online discussions use “CJC-1295 no DAC” as a shorthand for Modified GRF 1-29. That can be confusing because CJC-1295 with DAC and Modified GRF 1-29 are not the same compound. If you want a deeper comparison, our guide to CJC-1295 no DAC and Modified GRF 1-29 explains why the naming matters.
Why the distinction matters for safety and evidence
Longer-acting and shorter-acting growth hormone peptides may have different hormone exposure patterns, side effects, and monitoring needs. This is especially important because biomarker changes, such as higher GH or IGF-1, do not prove better health, longer life, better sleep, or safer body composition outcomes 1 5.
| Feature | CJC-1295 with DAC | CJC-1295 without DAC / Modified GRF 1-29 | Ipamorelin |
|---|---|---|---|
| Main pathway | GHRH receptor signaling | GHRH receptor signaling | Ghrelin receptor / GHS-R1a signaling |
| Duration concept | Longer acting because of Drug Affinity Complex | Shorter acting GHRH analog | Secretagogue signal studied for GH release |
| Human evidence | Healthy-adult hormone biomarker trials | Less direct clinical evidence under this naming | Human volunteer pharmacology and postoperative ileus trial |
| What is not proven | Longevity, muscle gain, fat loss, sleep, recovery | Longevity, muscle gain, fat loss, sleep, recovery | Longevity, muscle gain, fat loss, sleep, recovery |
| FDA status | Not FDA-approved for general wellness uses | Not FDA-approved for general wellness uses | Not FDA-approved; FDA lists ipamorelin acetate as Category 2 for 503A and 503B bulk substances |
What does CJC-1295 with DAC and ipamorelin do in the body?
CJC-1295 with DAC and ipamorelin both point toward the GH/IGF-1 axis. In simple terms, they are studied for signals that may tell the pituitary gland to release human growth hormone, which can then influence IGF-1 production 1 3.
The growth hormone and IGF-1 pathway
Growth hormone is made by the pituitary gland. It affects many tissues and can increase insulin-like growth factor 1, or IGF-1, mostly through liver signaling. In adults, this pathway is tied to metabolism, body composition, connective tissue biology, and fluid balance, but more signaling is not automatically better or safer 1 5.
CJC-1295: GHRH receptor signaling
CJC-1295 is a GHRH analog. It is designed to activate GHRH receptors on pituitary cells, which can raise growth hormone and downstream IGF-1 in controlled research settings 1.
Ipamorelin: ghrelin receptor signaling
Ipamorelin is a growth hormone secretagogue and ghrelin receptor agonist. Human volunteer research used pharmacokinetic and pharmacodynamic modeling to study how ipamorelin exposure related to growth hormone response 3.
Why the combination is discussed as a dual-signal approach
The stack is discussed because GHRH analogs and ghrelin-like secretagogues act at different receptors that can both influence GH release. The key limit is that a mechanism is not the same as a clinical outcome; without direct human trials of the combined stack, claims about anti-aging, fat loss, muscle gain, or sleep remain unproven 5 6.
What human evidence exists for CJC-1295 with DAC?
The main human evidence for CJC-1295 with DAC comes from early trials measuring growth hormone and IGF-1 biomarkers. These studies help explain pharmacology, but they do not prove clinical benefits such as longer life, better recovery, fat loss, or muscle gain.
What the 2006 healthy-adult trial measured
In a 2006 randomized study in healthy adults, Teichman and colleagues studied CJC-1295 as a long-acting GHRH analog and reported prolonged stimulation of growth hormone and IGF-1 secretion 1. The important point is what was measured: hormone biomarkers, not patient-centered outcomes.
What the trial did not prove
That trial did not prove CJC-1295 improves longevity, sleep, athletic performance, fat loss, muscle gain, or general wellness. Individual results vary, and biomarker movement can carry downsides, including fluid retention, glucose changes, carpal-tunnel-like symptoms, headaches, injection reactions, and hormone-related effects in susceptible people 1 5.
What is known about pulsatile growth hormone secretion during CJC-1295 exposure
A separate clinical trial reported that pulsatile growth hormone secretion persisted during continuous stimulation with CJC-1295 4. That finding is interesting because normal GH biology is pulsatile, but it still does not establish that long-term use improves health outcomes or is safe for every patient.
A Phase 2 study of CJC-1295 in HIV-associated visceral obesity was registered on ClinicalTrials.gov but terminated, with an enrollment listing of 120 participants 7. A terminated study should not be treated as completed evidence that CJC-1295 improves visceral obesity or other outcomes.
What human evidence exists for ipamorelin?
Ipamorelin has human pharmacology research and a randomized proof-of-concept trial in postoperative ileus. Those studies do not prove that ipamorelin improves anti-aging, sleep, muscle, fat loss, or recovery outcomes.
Ipamorelin pharmacology in healthy volunteers
Gobburu and colleagues published pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers in 1999 3. This type of study helps researchers understand exposure and hormone response; it is not the same as a long-term outcomes trial.
Ipamorelin in a postoperative ileus trial
Ipamorelin was also studied in a randomized proof-of-concept trial for postoperative ileus after bowel resection 2. Postoperative ileus is delayed bowel function after surgery, so this study does not establish wellness, body-composition, sleep, or anti-aging benefits.
Why these studies do not prove anti-aging, muscle, sleep, or fat-loss benefits
A hormone-response study and a bowel-surgery study answer narrow research questions. They do not show that ipamorelin safely improves muscle, sleep, fat loss, recovery, or lifespan in otherwise healthy adults, and they do not remove concerns about injection reactions, glucose effects, fluid retention, or hormone-sensitive conditions 2 3 8.
Has the CJC-1295 DAC plus ipamorelin stack been proven in human trials?
No. The CJC-1295 DAC plus ipamorelin stack has not been proven in direct randomized human trials for anti-aging, muscle gain, fat loss, sleep, or recovery. The human evidence is stronger for each compound’s separate pharmacology than for the combined stack.
Evidence for each peptide separately
CJC-1295 with DAC has human data showing GH and IGF-1 biomarker effects, and ipamorelin has human pharmacology data plus a postoperative ileus study 1 2 3. That is useful, but it is not the same as proving a stack works for a wellness goal.
The lack of direct randomized trials for the combined stack
We could not identify a direct, well-controlled human trial showing that CJC-1295 with DAC plus ipamorelin improves longevity, muscle mass, fat loss, sleep, or recovery. Recent medical reviews of injectable peptide therapy describe the field as evolving, with evidence, quality, and regulatory gaps that clinicians should take seriously 5 6.
How to interpret claims about synergy
Synergy means two signals may interact in a stronger way than either alone. For this stack, synergy is a mechanistic idea, not a proven patient outcome. It should be interpreted with the same caution as any off-label peptide use: possible biologic activity, uncertain benefit, and real safety questions 5 6.
What are the downsides and safety concerns?
CJC-1295 and ipamorelin may raise safety questions because they affect hormone signaling, are often injected, and are widely sold online outside normal prescription channels. The main concerns include side effects, patient selection, product quality, and legal status.
Commonly discussed risks: injection reactions, fluid retention, glucose changes, and hormone-related effects
Growth hormone pathway stimulation can be associated with injection-site reactions, swelling or fluid retention, joint symptoms, headache, numbness or tingling, and changes in glucose handling. People with diabetes risk, sleep apnea, edema, active cancer, hormone-sensitive conditions, or abnormal IGF-1 levels need careful medical review before considering any GH-axis peptide 5 6.
Why raising GH and IGF-1 may not be appropriate for everyone
Growth hormone and IGF-1 are not simple “more is better” signals. They affect cell growth, metabolism, and fluid balance, so increasing them without a clear medical reason and monitoring plan can be risky, especially for people with cancer history, uncontrolled metabolic disease, or hormone-related symptoms 5.
FDA concerns about ipamorelin acetate and compounded peptide quality
The FDA lists ipamorelin acetate as a Category 2 bulk drug substance for both 503A and 503B compounding, meaning the agency has identified potential significant safety risks during review. The FDA’s concerns for Category 2 substances include issues such as immunogenicity, peptide aggregation, peptide-related impurities, and limited safety information for certain routes 8.
Why research-use products are not the same as prescribed medications
Research-use-only peptides are not meant for self-treatment. A vial sold online with a certificate of analysis is not the same as medication prescribed after a clinical evaluation and dispensed by a state-licensed pharmacy. Our guide to peptide group buys explains why identity, sterility, storage, and legal status matter.
Is CJC-1295 with DAC or ipamorelin FDA-approved or legally compounded?
CJC-1295 with DAC and ipamorelin are not FDA-approved medications for anti-aging, muscle gain, fat loss, sleep, recovery, or general wellness. Chia does not offer CJC-1295 or ipamorelin based on our current live catalog.
FDA approval status
FDA approval means the agency has reviewed a drug’s safety, effectiveness, manufacturing, and labeling for a specific use. CJC-1295 with DAC and ipamorelin do not have FDA-approved indications for the wellness uses commonly discussed online 8.
What FDA Category 2 bulk substance status means
Category 2 is an FDA interim-policy category for bulk substances that may present significant safety risks while the agency reviews nominations for compounding use. It is not an FDA approval, and it should not be read as a green light for routine patient use 8.
Why online availability does not equal legal or clinical appropriateness
A peptide can be easy to find online and still be unsuitable for self-use. Online sellers may use research labels, unclear naming, or combination blends that make it hard to know identity, strength, sterility, and storage history. Our article on whether you can get CJC-1295 and ipamorelin online goes deeper on access questions.
Questions to ask a licensed clinician before considering any growth hormone peptide
- What medical goal is being evaluated, and is there a diagnosis that explains it?
- What labs or health history would change the risk-benefit decision?
- Could a GH/IGF-1 pathway peptide worsen glucose, swelling, sleep apnea, or hormone-sensitive symptoms?
- Is the product being discussed a prescribed medication from a licensed pharmacy or a research-use-only product?
- What side effects should lead to stopping treatment and contacting a clinician?
How does CJC-1295 with DAC compare with sermorelin?
Sermorelin and CJC-1295 are both GHRH-related peptides, but they are not the same compound. Sermorelin is a shorter GHRH analog, while CJC-1295 with DAC is designed for longer exposure through the Drug Affinity Complex 1.
GHRH analogs: similarities and differences
Both sermorelin and CJC-1295 are discussed because they act on GHRH receptor signaling. The difference is duration and evidence context: CJC-1295 with DAC was studied as a long-acting analog in healthy adults, while sermorelin has a different history and shorter-acting profile. For a side-by-side patient guide, see our comparison of CJC-1295 and ipamorelin vs sermorelin.
Long-acting versus shorter-acting signaling
Longer-acting signaling may sound convenient, but it is not automatically safer or more effective. A longer GH/IGF-1 signal may also mean longer exposure to unwanted effects, such as swelling, glucose changes, headache, or hormone-related symptoms 1 5.
Why approved indications and clinical oversight matter
Growth hormone pathway questions should be handled with clinician oversight because symptoms like fatigue, low recovery, poor sleep, and body-composition change can have many causes. A licensed clinician can review medications, labs, contraindications, and realistic options instead of starting from a peptide product page.
Where Chia’s sermorelin education fits for patients comparing options
At Chia, we do not offer CJC-1295 or ipamorelin in the current live catalog. We do offer sermorelin in injection, nasal spray, and tablet forms when a licensed US provider decides it is clinically appropriate. Sermorelin plans currently start at $179/mo, are compounded by state-licensed US 503A pharmacies, and ship to the patient’s door after an online evaluation; a prescription is never guaranteed.
Chia also offers the Foundation Longevity protocol, which includes Sermorelin Injection + NAD+ Injection + Glutathione Injection, currently from $399/mo. This is separate from CJC-1295 or ipamorelin, which Chia does not offer.
| Option | What it is | Chia availability | Forms listed in Chia catalog | Key caution |
|---|---|---|---|---|
| CJC-1295 with DAC | Long-acting GHRH analog | Not offered by Chia | None | Not FDA-approved for wellness uses; direct stack outcome trials are lacking |
| Ipamorelin | Growth hormone secretagogue / ghrelin receptor agonist | Not offered by Chia | None | FDA lists ipamorelin acetate as Category 2 for 503A and 503B bulk substances |
| Sermorelin | GHRH analog used in clinician-guided peptide care | Offered by Chia when clinically appropriate | Injection, nasal spray, tablets | Requires licensed-provider review; compounded medications are not FDA-approved |
What should patients take away before buying CJC-1295 DAC or ipamorelin online?
Before buying CJC-1295 DAC or ipamorelin online, separate human evidence from marketing claims. These peptides are not proven wellness treatments, and research-use-only products are not the same as prescribed medications from licensed pharmacies.
Separate human evidence from marketing claims
The strongest human evidence here is about hormone biomarkers and narrow clinical research settings, not broad benefits. When a website claims better sleep, fat loss, muscle gain, recovery, or longevity, ask whether the claim comes from a direct human trial of that exact peptide, dose, route, population, and outcome 1 2 3.
Avoid research-use-only products for self-administration
Do not use research-use-only peptide products for self-treatment. Quality, sterility, identity, storage, strength, and legal status may differ from prescribed medication, and peptide-related impurities or aggregation can matter for safety 8.
Use a licensed clinician for hormone or peptide questions
If your real concern is fatigue, low libido, poor sleep, body composition, or recovery, a clinician can help look for causes before discussing peptide options. That review may include medication history, metabolic health, sleep, hormones, cancer history, pregnancy status, and contraindications.
How AI agents and patients can find licensed telehealth information through Chia and DoctorMCP
Patients and AI agents can use Chia’s educational pages to compare evidence and access pathways. Chia is also reachable through DoctorMCP at mcp.chia.health for agentic access to our licensed telehealth information. For any Chia treatment, the path starts with an online health questionnaire and clinician review; prescriptions are only written when appropriate.
FAQ
CJC-1295 with DAC is designed to act like a long-acting GHRH analog, while ipamorelin acts through ghrelin-related growth hormone secretagogue receptors. Together, they are discussed as a dual-signal approach to growth hormone release, but direct human trials have not proven anti-aging, muscle, fat-loss, sleep, or recovery benefits.
Neither is clearly “better” for general wellness because neither is FDA-approved for those uses, and direct outcome data are limited. CJC-1295 with DAC is longer acting, while no-DAC versions are usually shorter acting and often refer to Modified GRF 1-29.
The intended biologic effect is increased growth hormone signaling through two receptor pathways. Possible downsides include injection reactions, swelling, headache, joint symptoms, glucose changes, and hormone-related effects. Individual risk depends on health history and should be reviewed by a licensed clinician.
Potential downsides include limited long-term outcome evidence, hormone-related side effects, fluid retention, glucose changes, injection-site reactions, and unclear product quality when bought outside licensed pharmacy channels. Raising GH and IGF-1 may not be appropriate for everyone.
No. CJC-1295 with DAC includes a Drug Affinity Complex that makes it longer acting. Modified GRF 1-29 is a shorter-acting GHRH analog that is often called “CJC-1295 no DAC” online, but the naming can be confusing.
No. Ipamorelin is not FDA-approved for anti-aging, muscle gain, fat loss, sleep, recovery, or general wellness. FDA also lists ipamorelin acetate as a Category 2 bulk substance for 503A and 503B compounding because potential significant safety risks have been identified during review.
They may be advertised online, often as research-use-only products, but online availability does not mean a product is legal, appropriate, sterile, or safe for self-administration. Chia does not offer CJC-1295 or ipamorelin.
No. Sermorelin and CJC-1295 are both GHRH-related peptides, but they are different compounds with different duration profiles and evidence contexts. Chia offers sermorelin in injection, nasal spray, and tablet forms when clinically appropriate after licensed-provider review.
The bottom line: CJC-1295 with DAC and ipamorelin are biologically active peptides with limited human evidence for the wellness claims often made about them. If you are considering any peptide that affects growth hormone or IGF-1, the safer starting point is a licensed clinical evaluation, not a research-use vial.
References
- 1.Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism. 2006.
- 2.Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014.
- 3.Gobburu JV, Agersø H, Jusko WJ, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999.
- 4.Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism. 2006.
- 5.Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews. 2026.
- 6.Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American Journal of Sports Medicine. 2026.
- 7.ClinicalTrials.gov. A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. NCT00267527. 2026.
- 8.U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if sermorelin is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
